Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Bone problems news

Show

From To
Ask A Pharmacist: With a new tenofovir, should you switch to Descovy, Genvoya or Odefsey?

I’ve heard more than a few patients ask, what should I do? If I’m already taking Complera, Stribild or Truvada, should I switch to the newer drug formulation with tenofovir alafenamide (TAF)?

Published
20 September 2016
From
BETA blog
Bone loss and recovery in MSM aged 13-24 using PrEP for a year

Results from an open-label study in young people using PrEP showed that impact on bone health might be important is daily dosing is used for many years.

Published
19 September 2016
From
HIV i-Base
Not So Fast: Do people with HIV really experience accelerated aging?

Recent talk about HIV and aging has almost always been scary. A number of studies conclude that people living with HIV have so-called “accelerated aging”—meaning they will suffer heart attacks, strokes, cancers, and osteoporosis more often and sooner than those without HIV. Well, this is one article on aging and HIV that will challenge the concept of people living with HIV having an early expiration date. Instead, we can look at what we know and what we don’t, to get a better idea of what the risks are for HIV-positive people growing older—and what they can do about them.

Published
08 July 2016
From
Positively Aware
Fearing Drugs’ Rare Side Effects, Millions Take Their Chances With Osteoporosis

Millions of Americans are missing out on a chance to avoid debilitating fractures from weakened bones, researchers say, because they are terrified of exceedingly rare side effects from drugs that can help them.

Published
02 June 2016
From
New York Times
A question of timing: A lawsuit claims Gilead Sciences could have developed a less-harmful version of its HIV treatment sooner

More than a decade ago, researchers at Gilead Sciences thought they had a breakthrough: a new version of the company’s key HIV medicine that was less toxic to kidneys and bones. But in 2004 Gilead executives stopped the research, only to restart it as the expiration of tenofovir’s patent in 2018 neared.

Published
30 May 2016
From
Los Angeles Times
HIV-infected young males have higher rates of bone loss than females

Accumulating evidence suggests that rates of low bone mass are greater in HIV-infected males than in females. Researchers led by Grace Aldrovandi, MD, chief of the Division of Infectious Diseases at Children's Hospital Los Angeles, studied 11 biomarkers associated with inflammation, bone loss and/or bone formation in about 450 individuals -- assessed by sex and HIV status -- to try to determine causes of this differential bone loss.

Published
11 March 2016
From
Eurekalert Medicine & Health
Free new tool for health providers to assist physical rehabilitation in people living with HIV

The free website, entitled "How Rehabilitation Can Help People Living with HIV in Sub-Saharan Africa: An Evidence-Informed Tool for Rehab Providers", was adapted from a Canadian resource and is also downloadable for use on paper. It's designed to be a one-stop resource for physiotherapists, occupational therapists and other health workers who can quickly and easily research the most common HIV-related disabilities, and find evidence-based rehabilitation solutions

Published
02 December 2015
From
Eurekalert Medicine & Health
TAF and TDF Compared for Kidney, Bone Toxicity in Black HIV+ Patients

Including tenofovir alafenamide (TAF) in single-tablet elvitegravir/cobicistat/emtricitabine (E/C/F/TAF) is associated with reduced renal and bone toxicity compared to tenofovir disoproxil fumarate (TDF)-containing single-tablet (E/C/F/TDF) therapy, according to an analysis of data from two Phase 3 trials, reported at IDWeek 2015.

Published
12 October 2015
From
Monthly Prescribing Reference
HIV Increases Bone Fracture Risk by 32% in Middle-Aged U.S. Women

HIV infection inflated the risk of a new fracture 32% in a mostly premenopausal group in the Women's Interagency HIV Study (WIHS). Older age, white race, previous fracture history, injection drug use, opiate use and smoking also independently raised the risk of any fracture in multivariate analysis.

Published
05 October 2015
From
The Body
Tenofovir Alafenamide Combo Pill Matches Truvada for HIV Efficacy, but Easier on Bones and Kidneys

A fixed-dose combination pill containing tenofovir alafenamide (TAF) worked as well in a Phase 3 trial as the current Truvada pill containing the older tenofovir disoproxil fumarate (TDF) -- which is used for both HIV treatment and pre-exposure prophylaxis or PrEP -- but causes less kidney and bone toxicity, according to an announcement this week from Gilead Sciences.

Published
04 September 2015
From
HIVandHepatitis.com
← First123...4Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close